Risk Assessment of Treatment-Related Liver Injury in Cancer Care

Abstract

Treatment-related liver injury (TRLI) is a significant complication in oncology, resulting from the hepatotoxic effects of chemotherapeutic agents, targeted therapies, immunotherapies, and supportive medications. This review provides an evidence-based overview of the incidence, mechanisms, risk factors, clinical manifestations, diagnostic strategies, and management of TRLI in cancer care. Recent advances, including biomarker development and risk stratification tools, as well as current guideline recommendations, are discussed to inform best practices and optimize patient outcomes.

Introduction

Oncologic therapies have revolutionized cancer outcomes but are frequently associated with adverse effects, including organ toxicities. Among these, treatment-related liver injury (TRLI) poses major challenges due to its potential to interrupt cancer therapy, impact prognosis, and increase morbidity. As the spectrum of anti-cancer agents expands, understanding the risk, pathophysiology, and management of TRLI is essential for clinicians to minimize harm and ensure therapeutic efficacy.

Epidemiology / Disease Burden

The incidence of TRLI varies depending on the type of cancer treatment and patient-specific factors. Conventional cytotoxic agents such as methotrexate, anthracyclines, and platinum compounds have well-documented hepatotoxicity profiles. Targeted therapies, notably tyrosine kinase inhibitors (TKIs), and immune checkpoint inhibitors (ICIs) also contribute to TRLI, with reported hepatotoxicity rates ranging from 2% to 20% in clinical trials. Real-world data suggest increased risk in patients with pre-existing liver disease, polypharmacy, or concomitant use of hepatotoxic supportive care drugs. TRLI is a leading cause of treatment modification or discontinuation, particularly in hepatocellular carcinoma and metastatic cancers with liver involvement.

Pathophysiology

TRLI encompasses a spectrum of hepatic injuries, including direct hepatocellular toxicity, cholestasis, vascular injury, and immune-mediated hepatitis. Cytotoxic agents may induce mitochondrial dysfunction, oxidative stress, and apoptosis, while targeted agents often disrupt signaling pathways critical for hepatic homeostasis. ICIs can trigger immune-mediated hepatitis through T-cell activation and loss of hepatic tolerance. Additionally, drug metabolism in the liver may produce reactive metabolites that induce idiosyncratic or dose-dependent injury. The pathophysiology is often multifactorial, influenced by genetic polymorphisms, underlying liver disease, and drug-drug interactions.

Risk Factors

Risk assessment for TRLI requires consideration of patient-specific and treatment-related factors. Host-related risks include chronic hepatitis B or C infection, alcoholic or nonalcoholic fatty liver disease, cirrhosis, older age, female sex, and genetic predispositions affecting drug metabolism (e.g., polymorphisms in CYP450 enzymes). Treatment-related risks involve cumulative drug dose, combination regimens, rapid infusion rates, and concurrent use of hepatotoxic drugs. The presence of liver metastases further increases susceptibility to injury. Recognizing these risk factors is critical for patient selection, monitoring, and prophylactic strategies.

Clinical Features

TRLI may present asymptomatically with isolated laboratory abnormalities or manifest as clinical syndromes such as acute hepatitis, cholestatic jaundice, or fulminant hepatic failure. Common findings include elevated serum aminotransferases, alkaline phosphatase, and bilirubin. Severe cases may progress to coagulopathy, encephalopathy, or multi-organ dysfunction, particularly in patients with pre-existing liver compromise. Immune-mediated hepatitis from ICIs often presents with delayed onset and may be associated with other immune-related adverse events.

Diagnosis

The diagnosis of TRLI is based on temporal association with oncologic therapy, exclusion of alternative etiologies (e.g., viral hepatitis, disease progression, sepsis), and characteristic laboratory and imaging findings. RUCAM (Roussel Uclaf Causality Assessment Method) and other causality scoring systems may aid in evaluating drug-induced liver injury. Liver biopsy is reserved for ambiguous or severe cases, particularly when immune-mediated pathology or vascular injury is suspected. Serological testing for viral hepatitis, autoimmune markers, and imaging studies (ultrasound, CT, MRI) are often warranted to assess liver architecture and exclude biliary obstruction or vascular compromise.

Treatment & Management

Management of TRLI involves prompt recognition, withdrawal or dose reduction of the offending agent, and supportive care. In cases of immune-mediated hepatitis, corticosteroids are first-line therapy, with escalation to mycophenolate mofetil or tacrolimus for refractory cases. Hepatoprotective agents such as N-acetylcysteine may be considered for acetaminophen-like toxicity. Close monitoring of liver function tests is mandatory during and after therapy modification. Multidisciplinary collaboration between oncology, hepatology, and pharmacy is essential to optimize outcomes and minimize treatment interruptions.

Recent Advances / Emerging Therapies

Recent advances in the field include the development of predictive biomarkers (e.g., microRNAs, cytokine profiles) and risk stratification models incorporating clinical and genetic variables. Emerging therapies, such as selective cytokine inhibitors, may hold promise for managing immune-mediated TRLI with greater specificity. Ongoing clinical trials are evaluating hepatoprotective agents and dose-modification strategies to mitigate TRLI without compromising oncologic efficacy. Additionally, next-generation sequencing and pharmacogenomics are being integrated into clinical practice to personalize risk assessment and therapy selection.

Guideline Recommendations

Major oncology and hepatology societies, including ASCO, ESMO, and AASLD, recommend baseline and periodic monitoring of liver function during cancer therapy, with more frequent testing in high-risk individuals. Early identification of hepatotoxicity, prompt intervention, and multidisciplinary management are emphasized. Guidelines advocate for temporary or permanent discontinuation of the causative agent in cases of severe injury, with consideration of alternative therapies where feasible. Prophylactic antiviral therapy is advised for patients with chronic hepatitis B receiving immunosuppressive or cytotoxic treatments.

Conclusion

Treatment-related liver injury remains a clinically significant and complex challenge in cancer care, necessitating a nuanced understanding of epidemiology, pathophysiology, and risk factors. Evidence-based risk assessment and vigilant monitoring are crucial to prevent severe hepatic complications and optimize cancer therapy outcomes. Future research focused on predictive biomarkers, targeted therapies, and personalized medicine approaches holds great promise for improving the safety and effectiveness of cancer treatment regimens. Collaborative care and adherence to guideline-based recommendations are essential for minimizing the burden of TRLI in oncology practice.